Neogenomics (NEO) Other Operating Expenses (2010 - 2026)

For the trailing twelve months through Sep 30, 2026, Other Operating Expenses at Neogenomics was $141.43 million, up 11.7% year-over-year; for FY2025, it came in at $129.04 million, up 11.9% from FY2024.

• Annual Other Operating Expenses shows a five-year compound annual growth rate of 18.1% (FY2020 to FY2025).
• In prior years, Neogenomics' Other Operating Expenses was $115.31 million in FY2024 (+19.6%), $96.45 million in FY2023 (-0.5%), $96.93 million in FY2022 (+14.8%) and $84.47 million in FY2021 (+50.6%).
• Quarterly Other Operating Expenses has run from a low of $22.73 million in Q1 2023 to a high of $38.04 million in Q2 2026 over five years.
• On a year-over-year basis, Other Operating Expenses has increased in each of the last 12 quarters, with growth averaging 13.3% over the last eight quarters.
• The strongest year-over-year quarter for Other Operating Expenses in the past five years was Q4 2021, with growth of 60.7%; the weakest was Q4 2022, with a decline of 5.4%.
• According to Business Quant data, Other Operating Expenses for the three prior quarters was $38.04 million (Q2 2026), $33.36 million (Q1 2026) and $32.58 million (Q4 2025).